Compare GTLS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLS | CYTK |
|---|---|---|
| Founded | 1859 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.0B |
| IPO Year | 1992 | 2004 |
| Metric | GTLS | CYTK |
|---|---|---|
| Price | $207.31 | $63.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $205.40 | $82.38 |
| AVG Volume (30 Days) | 534.9K | ★ 2.2M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $4,291,200,000.00 | $87,211,000.00 |
| Revenue This Year | $8.38 | $339.72 |
| Revenue Next Year | $11.36 | $79.08 |
| P/E Ratio | $240.36 | ★ N/A |
| Revenue Growth | 5.47 | ★ 2609.26 |
| 52 Week Low | $104.60 | $29.31 |
| 52 Week High | $220.03 | $70.98 |
| Indicator | GTLS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 71.73 | 50.00 |
| Support Level | $206.63 | $60.30 |
| Resistance Level | $206.96 | $65.35 |
| Average True Range (ATR) | 0.36 | 3.01 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 76.13 | 57.11 |
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.